Masimo Corporation
Masimo Announces Preliminary 2023 Results and 2024 Guidance
Summary
Masimo Corporation announced preliminary financial results for Q4 and full-year 2023, and provided guidance for full-year 2024. Consolidated revenue for Q4 was estimated between $541 million and $551 million, and for the full year between $2,041 million and $2,051 million. Full-year 2024 guidance includes consolidated revenue between $2,045 million and $2,165 million, and non-GAAP earnings per diluted share between $3.44 and $3.60. The preliminary results are subject to adjustments pending the completion of annual audit procedures.
Profitelligence Alerts
Get alerts for MASI
Be first to know when Masimo Corporation files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About Masimo Corporation
Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. The company's flagship product line includes advanced signal processing pulse oximetry devices, which are pivotal in accurately measuring oxygen levels, pulse rate, and other vital signals without the need for invasive procedures. Masimo's technology is widely adopted across various healthcare settings including hospitals, outpatient treatment centers, and alternative care sites, enhancing patient monitoring and aiding clinicians in detecting potential health issues more efficiently. Besides, Masimo’s products are recognized for their precision and reliability, demonstrating robustness even in challenging clinical environments where motion and low perfusion can affect monitoring accuracy. The corporation is committed to expanding its technological suite, covering a spectrum of health monitoring solutions that contribute to improved healthcare practices globally. Based in Irvine, California, Masimo's ongoing innovation continues to set benchmarks in the healthcare industry, influencing a wide range of sectors from emergency care to surgical and critical care monitoring.
Official SEC Documents
Advertisement